Project Grant R21AI190146

Award Date 7/1/25
Completion Date 6/30/27
Dollars Obligated $428K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Iowa City, IA 52242, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $158,260.00 to the University of Virginia to investigate the role of enteric glial cells (EGCs) in the pathogenesis of multiple sclerosis (MS). The project aims to characterize T cell responses against EGCs in an experimental autoimmune encephalomyelitis (EAE) model of MS and assess the impact of EGC ablation on disease onset and severity. This...
This Project Grant award of $1,527,730 from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA 93.855 Allergy and Infectious Diseases Research, supports a longitudinal study to elucidate the biological mechanisms underlying the association between Epstein-Barr virus (EBV) and multiple sclerosis (MS) in African Americans. The study will leverage pre-diagnostic serum samples and clinical data from over 480 African American participants (240 men, 240 women) to investigate...
The federal Project Grant award R21AI187838, totaling $451,000.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research at the University of Chicago to investigate how a retrovirus, such as the mouse mammary tumor virus (MMTV), may manipulate antibody responses in B cells to evade the host's protective immunity. The research aims to determine if the retrovirus...
This Project Grant award of $305,000.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the role of stem-like T cells in multiple sclerosis (MS) disease progression. The key objectives are to: Rigorously test the hypothesis that a continuing stemness and differentiation of CD4+ T stem cells results in functional and transcriptomic diversification under evolving...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $471,159 to the University of California, Irvine to conduct research on the role of interferon lambda in alpha herpesvirus neuroinvasion. The research aims to elucidate the mechanisms of local axonal responses to interferon lambda and their effects on viral invasion of the nervous system, as well as how these...
This three-year $872,936 project grant from the National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, will fund research into the regulation of the microglial neuroimmune response by long non-coding RNAs. The grantee, Creighton University, will investigate how specific long intergenic non-coding RNAs (lincRNAs) mediate a proinflammatory state in microglia and determine if differential lincRNA expression underlies viral-induced mouse models of...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $416,121.00 to Rutgers, The State University of New Jersey to conduct research on the role of Tbet+ B cells in viral reinfection. The research aims to elucidate how the developmental origin of Tbet+ B cells (germinal center vs. extrafollicular) influences their differentiation and function following secondary viral...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $924,000 to New York Medical College to discover and characterize the first-in-world small molecule inhibitors of the Epstein-Barr virus (EBV) protein BPLF1, which has deubiquitinating activity. The award aims to use high-throughput screening to identify novel chemotypes for lead optimization and further validate...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $427,625 to The University of Iowa to investigate the mechanisms by which measles virus (MEV) spreads rapidly through airway epithelial cells. The research aims to confirm that MEV utilizes a membrane fusion apparatus (MFA) consisting of three viral proteins to open intercellular pores, allowing the viral ribonucleoprotein complex to pass...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $138,051 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Regents of the University of Minnesota. The grant supports research to understand the role of thymic B cells in regulating immune tolerance and autoimmune diseases. The research aims to investigate how type-III interferon-driven licensing of thymic B cells impacts the development of T regulatory cells that become...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $427,627 to The University of Iowa to investigate how gamma herpesvirus (GHV) infection impacts B cell-dependent interactions that drive autoimmune demyelinating disease in a mouse model of multiple sclerosis (MS). The research aims to determine how GHV infection, such as Epstein-Barr virus, affects B cells' support of disease-driving CD4 T cells, and how this impacts B cell-dependent versus B cell-independent experimental autoimmune encephalomyelitis (EAE) in mice. This 2-year project, running from July 1, 2025 to June 30, 2027, will leverage the university's expertise to develop a novel mouse model that can better dissect the role of pathogenic B cell-CD4 T cell interactions in autoimmune demyelinating disease in the context of viral infection, providing insights that may inform future MS treatment approaches.

Generated 7/15/25, 11:45 AM